Comparative Pharmacology
Head-to-head clinical analysis: SIGNIFOR LAR KIT versus SOMATULINE DEPOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIGNIFOR LAR KIT versus SOMATULINE DEPOT.
SIGNIFOR LAR KIT vs SOMATULINE DEPOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Somatostatin analog that binds to somatostatin receptors (primarily sst2 and sst5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, and reducing hormone release from neuroendocrine tumors.
Somatostatin analog; binds to somatostatin receptors (mainly SSTR2 and SSTR5) with high affinity, inhibiting the secretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), and various gastrointestinal hormones.
Intramuscular injection: 40 mg every 28 days.
90 mg subcutaneously every 4 weeks for acromegaly; 120 mg subcutaneously every 4 weeks for neuroendocrine tumors (administered every 2 weeks if progression occurs). Adjust dose based on clinical response and growth hormone/IGF-1 levels.
None Documented
None Documented
Terminal elimination half-life following intramuscular injection of the long-acting formulation is approximately 19 days (range 15–23 days), supporting monthly dosing intervals.
The terminal elimination half-life is approximately 23-29 days after subcutaneous injection of the depot formulation, supporting a monthly dosing interval.
Primarily renal (approximately 85% of administered dose excreted unchanged in urine); minimal biliary/fecal excretion (less than 10%).
Lanreotide is primarily excreted via the biliary-fecal route. After administration, approximately 78% of a radiolabeled dose is recovered in feces, with less than 5% excreted unchanged in urine. The remainder is metabolized and eliminated via bile.
Category C
Category C
Somatostatin Analog
Somatostatin Analog